Yonkenafil Hydrochloride

Yonkenafil Hydrochloride Suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354;
Email: support@targetmol.com
Products Intro: Product Name:Yonkenafil HCl；Yonkenafil hydrochloride
CAS:804519-64-0
Package:100 mg；500 mg Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: TargetMol Chemicals Inc.
Tel: +17819995354
Email: marketing@targetmol.com
Products Intro: Product Name:Yonkenafil HCl
CAS:804519-64-0
Package:100mg;2360USD|25mg;1140USD|50mg;1490USD
Company Name: NINGBO SYNTAME BIOTECH CO LTD  
Tel: +86-0574-28802872 18668283131
Email: sales@syntame.com
Products Intro: Product Name:Yonkenafil Hydrochloride
CAS:804519-64-0
Purity:99%+
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Products Intro: Product Name:Yonkenafil HCl
CAS:804519-64-0
Package:100mg/RMB 22800;25mg/RMB 11200;50mg/RMB 14600

Yonkenafil Hydrochloride manufacturers

  • Yonkenafil HCl
  • Yonkenafil HCl pictures
  • $2360.00
  • 2026-05-11
  • CAS:804519-64-0
  • Purity:
  • Supply Ability: 10g
Yonkenafil Hydrochloride Basic information
Product Name:Yonkenafil Hydrochloride
Synonyms:Yonkenafil Hydrochloride;Yonkenafil HCl
CAS:804519-64-0
MF:C24H34ClN5O4S
MW:524.08
EINECS:
Product Categories:
Mol File:804519-64-0.mol
Yonkenafil Hydrochloride Structure
Yonkenafil Hydrochloride Chemical Properties
form Solid
color Off-white to light yellow
Safety Information
MSDS Information
Yonkenafil Hydrochloride Usage And Synthesis
DescriptionYonkenafil HCl is a PDE5 inhibitor potentially for the treatment of erectile dysfunction.
UsesYonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease[1].
in vivo

Yonkenafil (Tunodafil) hydrochloride (4-32 mg/kg, i.v. daily for 7days) improves behavioral outcomes after stroke and reduces cerebral infarct volume, inhibits neuronal apoptosis, and significantly enhances synaptic function in ischemic brain by modulating the expression of BDNF/TrkB and NGF/TrkA[1].

Animal Model:Male Sprague-Dawley (SD) Rat[1]
Dosage:4, 8, 16 and 32mg/kg
Administration:i.v. daily for 7days
Result:Induced a dose-dependent decrease in infarct volume, with an ED50 of 12.27 mg/kg.
Increased hsp70 expression, decreased apaf-1 expression, and inhibited caspase-3 and caspase-9 cleavage.
Significantly prevented neuronal damage and increases the number of surviving neurons after stroke.
Prevented decrease in synaptophysin levels and increase in PSD-95 and nNOS levels.
IC 50PDE5
References[1] Xuemei Chen, et al. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. Exp Neurol. 2014 Nov;261:267-77. DOI:10.1016/j.expneurol.2014.07.007
Yonkenafil Hydrochloride Preparation Products And Raw materials
Tag:Yonkenafil Hydrochloride(804519-64-0) Related Product Information